Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cannabigerol

Phase 1Small molecule

WWashington State University

1

Indications

3

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Metastatic Bladder CancerNot yet recruiting

Non-Metastatic Bladder CancerPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Non-Metastatic Bladder Cancer

NCT07577999

Clinical

Trials by Indication[1]

Acute1 trial

Acute Effects of Cannabigerol

Completed·WWashington State University·Phase 1·NCT05257044·34 enrolled

Attention Deficit Hyperactivity Disorder1 trial

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

Recruiting·UUniversity of Arkansas, Fayetteville·Phase 2·NCT06115603·76 enrolled

Non-metastatic Bladder Cancer1 trial

The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy

Not yet recruiting·SStanford University·Phase 1·NCT07577999·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cannabigerol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cannabigerol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cannabigerol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington State University

Related News